| scholarly article | Q13442814 |
| P50 | author | Ernst R Werner | Q41776119 |
| G Werner-Felmayer | Q67236554 | ||
| P2093 | author name string | Gerald Brandacher | |
| Peter Obrist | |||
| Dietmar Fuchs | |||
| Georg Göbel | |||
| Raimund Margreiter | |||
| Albert Amberger | |||
| Alfred Königsrainer | |||
| Ruth Ladurner | |||
| Stefan Schneeberger | |||
| Christiana Winkler | |||
| Alexander Perathoner | |||
| Helmut G Weiss | |||
| P2860 | cites work | Prevention of allogeneic fetal rejection by tryptophan catabolism | Q24336018 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 1144-1151 | |
| P577 | publication date | 2006-02-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells | |
| P478 | volume | 12 |
| Q41582112 | (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells |
| Q35744133 | 1-Methyl-D-tryptophan potentiates TGF-β-induced epithelial-mesenchymal transition in T24 human bladder cancer cells. |
| Q38936995 | 1-butyltryptophan inhibits cell proliferation, migration, and invasion through the Akt pathway in human gastric cancer cells |
| Q36635458 | A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy |
| Q46891007 | A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase |
| Q37225714 | A phase I study of indoximod in patients with advanced malignancies |
| Q42925924 | A potential role for indoleamine 2,3-dioxygenase (IDO) in Rhodococcus equi infection |
| Q35584153 | A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy |
| Q35604318 | Accumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancers |
| Q61809693 | Accumulation of exhausted CD8+ T cells in extramammary Paget's disease |
| Q89965594 | Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib |
| Q35952614 | Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases |
| Q35261125 | Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. |
| Q38263409 | Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? |
| Q37357710 | An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells |
| Q28547142 | An Autocrine Cytokine/JAK/STAT-Signaling Induces Kynurenine Synthesis in Multidrug Resistant Human Cancer Cells |
| Q35850187 | Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry |
| Q38739230 | Assessment of Tryptophan Uptake and Kinetics Using 1-(2-18F-Fluoroethyl)-l-Tryptophan and α-11C-Methyl-l-Tryptophan PET Imaging in Mice Implanted with Patient-Derived Brain Tumor Xenografts |
| Q46047267 | Biomimetic synthesis of the IDO inhibitors exiguamine A and B. |
| Q28085084 | Breath analysis as a potential and non-invasive frontier in disease diagnosis: an overview |
| Q56892062 | CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer |
| Q101573919 | Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy |
| Q38647681 | Challenges in the design of reliable immuno-oncology mouse models to inform drug development. |
| Q54698804 | Clinical significance of simultaneous determination of serum tryptophan and tyrosine in patients with lung cancer. |
| Q35653808 | Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer |
| Q33751144 | Combination of physical activity, nutrition, or other metabolic factors and vaccine response |
| Q37579669 | Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma. |
| Q33572246 | Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. |
| Q64243032 | Control of the Antitumor Immune Response by Cancer Metabolism |
| Q38260051 | Designing effective vaccines for colorectal cancer. |
| Q36265787 | Development of 1-N-(11)C-Methyl-L- and -D-Tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-Methyl-Tryptophan |
| Q99711521 | Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses |
| Q34336127 | Differential kinetics of α-[¹¹C]methyl-L-tryptophan on PET in low-grade brain tumors |
| Q48589619 | Discovery of IDO1 and DNA dual targeting antitumor agents. |
| Q36198024 | Discovery of a Novel Scaffold as an Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Based on the Pyrrolopiperazinone Alkaloid, Longamide B. |
| Q39272251 | Dysfunctional T cell metabolism in the tumor microenvironment |
| Q64100339 | Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review |
| Q46698119 | Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation |
| Q39249589 | Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel |
| Q41470807 | Evaluation of radiofluorinated carboximidamides as potential IDO-targeted PET tracers for cancer imaging |
| Q90678032 | Exercise as Adjunct Therapy in Cancer |
| Q89849938 | Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions |
| Q35406476 | Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma |
| Q39988114 | Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma |
| Q39404674 | Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation |
| Q33684895 | Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach |
| Q39351950 | Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach |
| Q46182219 | Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells |
| Q30931726 | Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytes |
| Q37568540 | Fatty acid-binding protein 1 is preferentially lost in microsatellite instable colorectal carcinomas and is immune modulated via the interferon γ pathway |
| Q55400645 | First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. |
| Q34546698 | Formation of an N-formylkynurenine-derived fluorophore and its use for measuring indoleamine 2,3-dioxygenase 1 activity |
| Q36620776 | Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity |
| Q38531261 | Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target |
| Q35221827 | Helicobacter pylori and serum kynurenine-tryptophan ratio in patients with colorectal cancer |
| Q60922978 | High Expression of Indoleamine 2, 3-Dioxygenase in Adenosquamous Lung Carcinoma Correlates with Favorable Patient Outcome |
| Q35175306 | High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes |
| Q38047057 | Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. |
| Q37872644 | How tumors might withstand γδ T-cell attack. |
| Q28551043 | IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells |
| Q50103704 | IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients |
| Q90479641 | IDO Targeting in Sarcoma: Biological and Clinical Implications |
| Q43263135 | IDO and outcomes in ovarian cancer |
| Q35645172 | IDO and regulatory T cell support are critical for cytotoxic T lymphocyte-associated Ag-4 Ig-mediated long-term solid organ allograft survival. |
| Q36861514 | IDO expression in the brain: a double-edged sword |
| Q34512092 | IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance |
| Q38728766 | IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease |
| Q36944802 | IDO-expressing regulatory dendritic cells in cancer and chronic infection |
| Q47836812 | IDO1 in cancer: a Gemini of immune checkpoints. |
| Q37042990 | IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice |
| Q95660974 | IDO1+ Paneth cells promote immune escape of colorectal cancer |
| Q46139845 | Identification of immunologically relevant genes in mare and foal dendritic cells responding to infection by Rhodococcus equi |
| Q35753251 | Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. |
| Q89217952 | Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies |
| Q38445709 | Immune Therapy in GI Malignancies: A Review |
| Q91272360 | Immune control by amino acid catabolism during tumorigenesis and therapy |
| Q37535138 | Immune escape mechanisms of intraocular tumors |
| Q35806782 | Immunity, cancer and aging: lessons from mouse models. |
| Q52727105 | Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium. |
| Q37144901 | Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. |
| Q96953606 | Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies |
| Q35603131 | Immunosuppressive tumor microenvironment in cervical cancer patients |
| Q36996316 | Immunotherapy and immunoescape in colorectal cancer. |
| Q53111596 | Immunotherapy for Colorectal Cancer. |
| Q53183990 | Immunotherapy in Gastrointestinal Cancers. |
| Q36114649 | Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. |
| Q26825202 | Implication of indolamine 2,3 dioxygenase in the tolerance toward fetuses, tumors, and allografts |
| Q36591970 | Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma |
| Q64981776 | Indoleamine 2, 3-dioxygenase 1 promoter hypomethylation is associated with poor prognosis in patients with esophageal cancer. |
| Q51502194 | Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B. |
| Q27025063 | Indoleamine 2,3 dioxygenase in intestinal disease |
| Q64923604 | Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer. |
| Q36526999 | Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. |
| Q33688517 | Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. |
| Q51089138 | Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor. |
| Q63366136 | Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells |
| Q36866163 | Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer |
| Q37798692 | Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer |
| Q36809762 | Indoleamine 2,3-dioxygenase and tumor-induced tolerance |
| Q35048483 | Indoleamine 2,3-dioxygenase expression and activity in patients with hepatitis C virus-induced liver cirrhosis |
| Q60921434 | Indoleamine 2,3-dioxygenase expression and overall survival in patients diagnosed with breast cancer in Pakistan |
| Q43115659 | Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy |
| Q34655953 | Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. |
| Q38132933 | Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012). |
| Q36612457 | Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer |
| Q39126900 | Indoleamine 2,3-dioxygenase levels at the normal and recurrent spontaneous abortion fetal-maternal interface |
| Q37362632 | Indoleamine 2,3-dioxygenase: is it an immune suppressor? |
| Q35506234 | Indoleamine-2,3-dioxygenase (IDO) metabolic activity is detrimental for cervical cancer patient survival |
| Q54968700 | Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer. |
| Q97421870 | Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1 |
| Q39327066 | Induction of indoleamine-2,3 dioxygenase in bone marrow stromal cells inhibits myeloma cell growth |
| Q90176765 | Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer |
| Q93185054 | Inhibition of Indoleamine 2,3 Dioxygenase Does Not Improve Cancer-Related Symptoms in a Murine Model of Human Papilloma Virus-Related Head and Neck Cancer |
| Q42089828 | Inhibition of indoleamine 2,3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice. |
| Q34616168 | Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. |
| Q37492248 | Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? |
| Q50043586 | Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine |
| Q34819340 | Interferon-γ-induced inflammatory markers and the risk of cancer: the Hordaland Health Study |
| Q40210981 | Intestinal epithelial suppressor of cytokine signaling 3 (SOCS3) impacts on mucosal homeostasis in a model of chronic inflammation |
| Q33865610 | Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma |
| Q35370968 | Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma |
| Q34556982 | Involvement of the kynurenine pathway in human glioma pathophysiology |
| Q37026760 | Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? |
| Q35507380 | Kynurenine and uric acid levels in chronic myeloid leukemia patients. |
| Q52714204 | LW106, A Novel Inhibitor of IDO1, Suppresses Tumor Progression by Limiting Stroma-Immune Crosstalk and Cancer Stem Cell Enrichment in the Tumor Microenvironment. |
| Q35949858 | Ligand migration in human indoleamine-2,3 dioxygenase |
| Q39936938 | Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas |
| Q90254034 | Low-dose X-ray radiotherapy-radiodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immunotherapy |
| Q92646824 | MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer |
| Q89965694 | Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain |
| Q37522460 | Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases |
| Q41808459 | Mechanisms of local immunosuppression in cutaneous melanoma. |
| Q39930421 | Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. |
| Q39197674 | Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment |
| Q48306002 | Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. |
| Q37732704 | Molecular imaging and targeted therapies |
| Q53827700 | New Therapies in Head and Neck Cancer. |
| Q34393455 | Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion |
| Q42690881 | Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer |
| Q97424238 | Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy |
| Q38262255 | Overcoming tumor-mediated immunosuppression |
| Q60301541 | Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype |
| Q48442798 | Oxidative stress and tryptophan degradation pattern of acute Toxoplasma gondii infection in mice |
| Q38579710 | Parallel Expression of Enzyme Inhibitors of CD8T Cell Activity in Tumor Microenvironments and Secretory Endometrium |
| Q55351202 | Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile. |
| Q49071066 | Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? |
| Q46608363 | Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy |
| Q92261136 | Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours |
| Q55346219 | Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. |
| Q41920092 | Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients |
| Q38718929 | Prevention and treatment of cancers by immune modulating nutrients. |
| Q39336624 | Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma |
| Q43267301 | Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma |
| Q48182026 | Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status |
| Q37445396 | Quantification of tryptophan transport and metabolism in lung tumors using PET. |
| Q58094184 | Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis |
| Q36747510 | Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma |
| Q35799094 | Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. |
| Q60046359 | Role of indoleamine 2,3-dioxygenase in pathology of the gastrointestinal tract |
| Q39814919 | Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma |
| Q36729425 | Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression |
| Q91743156 | Salmonella-Based Targeted Cancer Therapy: Updates on A Promising and Innovative Tumor Immunotherapeutic Strategy |
| Q92062473 | Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth |
| Q35805226 | Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis |
| Q33482453 | Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer |
| Q64067882 | Sodium Sulfite Exacerbates Allograft Vasculopathy and Affects Tryptophan Breakdown in Murine Heterotopic Aortic Transplantation |
| Q39670159 | Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels |
| Q34653844 | Substrate and cofactor requirements of indoleamine 2,3-dioxygenase in interferon-gamma-treated cells: utilization of oxygen rather than superoxide |
| Q37829355 | Suppression of T-cell responses by tumor metabolites |
| Q50502824 | Suppression of azoxymethane-induced colonic preneoplastic lesions in rats by 1-methyltryptophan, an inhibitor of indoleamine 2,3-dioxygenase. |
| Q48334858 | Synthesis and Molecular Modeling Studies of N'-Hydroxyindazolecarboximidamides as Novel Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. |
| Q36753355 | T and NK cells: two sides of tumor immunoevasion |
| Q64229427 | Targeting Immune-Related Molecules in Cancer Therapy: A Comprehensive Analysis on Patient-Derived Tumor Models |
| Q26775425 | Targeting amino acid metabolism in cancer growth and anti-tumor immune response |
| Q37352554 | Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy |
| Q26775471 | Targeting the indoleamine 2,3-dioxygenase pathway in cancer |
| Q34550440 | Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. |
| Q28275608 | The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells |
| Q99404833 | The Prognostic Value of Indoleamine-2,3-Dioxygenase Gene Expression in Urine of Prostate Cancer Patients Undergoing Radical Prostatectomy as First Treatment of Choice |
| Q35884237 | The Role of Indoleamine 2,3-Dioxygenase in Diethylnitrosamine-Induced Liver Carcinogenesis |
| Q46579742 | The correlation between the subsets of tumor infiltrating memory T cells and the expression of indoleamine 2,3-dioxygenase in gastric cancer |
| Q37959968 | The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance |
| Q53146697 | The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma. |
| Q37831426 | The immunoregulatory mechanisms of carcinoma for its survival and development |
| Q28744405 | The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells |
| Q37329058 | The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer |
| Q38356502 | The potential of targeting indoleamine 2,3-dioxygenase for cancer treatment. |
| Q36117580 | The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth |
| Q59469171 | The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. |
| Q26830399 | The role of IDO in brain tumor immunotherapy |
| Q60442132 | The role of plasma IDO activity as a diagnostic marker of patients with colorectal cancer |
| Q41149149 | The status of immunosuppression in patients with stage IIIB or IV non-small-cell lung cancer correlates with the clinical characteristics and response to chemotherapy |
| Q50803151 | The subsets of dendritic cells and memory T cells correspond to indoleamine 2,3-dioxygenase in stomach tumor microenvironment. |
| Q91826310 | The therapeutic potential of targeting tryptophan catabolism in cancer |
| Q36593753 | The tumor-draining lymph node as an immune-privileged site |
| Q38571347 | Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. |
| Q27006866 | Trial watch: IDO inhibitors in cancer therapy |
| Q92131878 | Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy |
| Q33912950 | Tryptophan degradation in women with breast cancer: a pilot study |
| Q91559758 | Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond |
| Q92905230 | Tumor Metabolism as a Regulator of Tumor-Host Interactions in the B-Cell Lymphoma Microenvironment-Fueling Progression and Novel Brakes for Therapy |
| Q37836612 | Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance |
| Q52873461 | Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers. |
| Q37046717 | Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma |
| Q39514618 | Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma |
| Q37111136 | Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer |
| Q26773472 | Understanding the role of the kynurenine pathway in human breast cancer immunobiology |
| Q37640243 | Untargeted metabolomics of colonic digests reveals kynurenine pathway metabolites, dityrosine and 3-dehydroxycarnitine as red versus white meat discriminating metabolites |
| Q52643529 | Updates on immunotherapy for colorectal cancer. |
| Q35248373 | Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells |
| Q35450360 | Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis |
| Q37224538 | Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion |
| Q52569152 | miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy. |
| Q92480951 | miR-448 targets IDO1 and regulates CD8+ T cell response in human colon cancer |
Search more.